Special drug use survey of Tremfya for palmoplantar pustulosis
Not Applicable
- Conditions
- palmoplantar pustulosis
- Registration Number
- JPRN-UMIN000036102
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of the use of ustekinumab (active ingredient of this product)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variables related to safety a.Data on adverse reactions/infection b.Data on adverse reactions of primary survey items c.Factors possibly affecting the safety d.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) e.Data on adverse reactions of malignancy after long term of administration Variables related to efficacy a.efficacy (PPPASI) b.Factors possibly affecting the efficacy c.Investigation of the efficacy in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder)
- Secondary Outcome Measures
Name Time Method